Fatty liver drug trial in HIV patients stalls after enrolling just 4 people
NCT ID NCT05211284
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a drug called saroglitazar magnesium for nonalcoholic fatty liver disease (NAFLD) in people with HIV. The trial aimed to see if the drug could reduce liver fat over 24 weeks. However, the study was terminated early and only enrolled 4 participants, so no meaningful results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Saroglitazar magnesium
What this could lead to
If it works, this could point toward a treatment for fatty liver disease in people living with HIV.
What could go wrong
This was a very small, early-phase trial that was terminated early with only 4 participants. Results are not available, so we cannot draw any conclusions about safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zydus US001
Durham, North Carolina, 27710, United States
-
Zydus US002
Indianapolis, Indiana, 46202, United States
-
Zydus US003
Baltimore, Maryland, 21287, United States
-
Zydus US004
Birmingham, Alabama, 35294-2050, United States
-
Zydus US005
La Jolla, California, 92037, United States
-
Zydus US006
San Francisco, California, 94143, United States
-
Zydus US007
Houston, Texas, 77030, United States
-
Zydus US008
Richmond, Virginia, 23298, United States